---
title: "RLFTF.US (RLFTF.US) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/RLFTF.US/news.md"
symbol: "RLFTF.US"
name: "RLFTF.US"
parent: "https://longbridge.com/zh-CN/quote/RLFTF.US.md"
datetime: "2026-03-13T18:04:06.823Z"
locales:
  - [en](https://longbridge.com/en/quote/RLFTF.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RLFTF.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RLFTF.US/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/RLFTF.US/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/RLFTF.US/news.md)


# RLFTF.US (RLFTF.US) — 相关新闻

### [MindMaze Therapeutics Appoints HealthTech Veteran Zach Henderson as CEO to Accelerate Global Commercial Scale](https://longbridge.com/zh-CN/news/278843742.md)
*2026-03-12T07:50:57.000Z*
> In Geneva, MindMaze Therapeutics Holding SA (SIX: MMTX) appointed Zach Henderson as their new Chief Executive Officer. T

### [MindMaze Names New CEO to Drive U.S. Expansion and Scale AI Neurotherapies](https://longbridge.com/zh-CN/news/278830877.md)
*2026-03-12T06:34:39.000Z*
> MindMaze Names New CEO to Drive U.S. Expansion and Scale AI Neurotherapies

### [MindMaze Therapeutics Provides Corporate Update and Publishes March 2026 Investor Presentation](https://longbridge.com/zh-CN/news/277581075.md)
*2026-03-03T07:45:00.000Z*
> MindMaze Therapeutics has provided a corporate update and published its March 2026 investor presentation. CEO Alexandre 

### [MindMaze Therapeutics (SIX: MMTX) updates on corporate progress and releases March 2026 investor presentation. CEO aims for expansion.](https://longbridge.com/zh-CN/news/277579165.md)
*2026-03-03T07:13:16.000Z*
> In Geneva, MindMaze Therapeutics Holding SA (SIX: MMTX) shared a post-listing corporate update and released its March 20

### [Relief Therapeutics Holding AG Announces New Exclusive Definitive License Agreement for OLPRUVA(TM) (ACER-001) with Acer Therapeutics](https://longbridge.com/zh-CN/news/96599395.md)
*2023-08-30T21:40:00.000Z*
> (marketscreener.com) Relief Therapeutics Holding AG announced it has entered into a new exclusive definitive licensing a